Media stories about Uroplasty (NASDAQ:UPI) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Uroplasty earned a news impact score of 0.09 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 45.1941115884402 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
UPI stock remained flat at $$1.22 during mid-day trading on Friday. Uroplasty has a 52-week low of $1.05 and a 52-week high of $4.05.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Uroplasty (UPI) Share Price” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.wkrb13.com/2018/03/31/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-uroplasty-upi-share-price.html.
Uroplasty Company Profile
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.